Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration by Pellegrini, Carolina et al.
RESEARCH Open Access
Alteration of colonic excitatory
tachykininergic motility and enteric
inflammation following dopaminergic
nigrostriatal neurodegeneration
Carolina Pellegrini1†, Matteo Fornai1*†, Rocchina Colucci2, Erika Tirotta1, Fabio Blandini3, Giovanna Levandis3,
Silvia Cerri3, Cristina Segnani1, Chiara Ippolito1, Nunzia Bernardini1, Karolina Cseri4, Corrado Blandizzi1,
György Haskó5 and Luca Antonioli1,5
Abstract
Background: Parkinson’s disease (PD) is frequently associated with gastrointestinal (GI) symptoms, including
constipation and defecatory dysfunctions. The mechanisms underlying such disorders are still largely unknown,
although the occurrence of a bowel inflammatory condition has been hypothesized. This study examined the
impact of central dopaminergic degeneration, induced by intranigral injection of 6-hydroxydopamine (6-OHDA),
on distal colonic excitatory tachykininergic motility in rats.
Methods: Animals were euthanized 4 and 8 weeks after 6-OHDA injection. Tachykininergic contractions, elicited
by electrical stimulation or exogenous substance P (SP), were recorded in vitro from longitudinal muscle colonic
preparations. SP, tachykininergic NK1 receptor, and glial fibrillary acidic protein (GFAP) expression, as well as the
density of eosinophils and mast cells in the colonic wall, were examined by immunohistochemical analysis.
Malondialdehyde (MDA, colorimetric assay), TNF, and IL-1β (ELISA assay) levels were also examined. The polarization
of peritoneal macrophages was evaluated by real-time PCR.
Results: In colonic preparations, electrically and SP-evoked tachykininergic contractions were increased in 6-OHDA
rats. Immunohistochemistry displayed an increase in SP and GFAP levels in the myenteric plexus, as well as NK1
receptor expression in the colonic muscle layer of 6-OHDA rats. MDA, TNF, and IL-1β levels were increased also
in colonic tissues from 6-OHDA rats. In 6-OHDA rats, the number of eosinophils and mast cells was increased as
compared with control animals, and peritoneal macrophages polarized towards a pro-inflammatory phenotype.
Conclusions: The results indicate that the induction of central nigrostriatal dopaminergic degeneration is followed
by bowel inflammation associated with increased oxidative stress, increase in pro-inflammatory cytokine levels,
activation of enteric glia and inflammatory cells, and enhancement of colonic excitatory tachykininergic motility.
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Background
Gastrointestinal (GI) symptoms in Parkinson’s disease
(PD), such as dysphagia, nausea, delayed gastric empty-
ing, abdominal distension, and chronic constipation,
represent prominent non-motor features of the disease,
which often precede the onset of typical motor symp-
toms [1, 2]. Such GI disturbances contribute to the mor-
bidity of PD, complicating its clinical management [3, 4].
Changes in enteric nervous system (ENS) have been pro-
posed to be involved in the onset and development of
digestive symptoms in PD, and there is evidence that
they represent one of the earliest signs of the disease, as
suggested also by the presence of α-synuclein-positive
inclusions (Lewy bodies), the typical hallmarks of PD, in
neurons of the myenteric plexus of PD patients [4].
However, little is known about the neurochemical, mo-
lecular and functional changes occurring in the GI tract
in the presence of PD.
Both pre-clinical and human studies have shown that
PD is associated with functional GI changes [2]. In
particular, animals with PD-like features, induced by sys-
temic injection of specific neurotoxins, as well as trans-
genic mice overexpressing mutant A53T α-synuclein,
were found to display moderate GI dysfunctions, includ-
ing reduced gastric emptying, prolonged GI transit time
and decreased fecal output [5–7]. Other authors re-
ported the occurrence of GI dysmotility following 6-
hydroxydopamine (6-OHDA) injection into the medial
forebrain bundle (MFB) of rats, a well-known procedure
inducing massive degeneration of dopaminergic neurons
in the substantia nigra [8]. In particular, alterations of
enteric neurotransmitters (dopamine, nitric oxide, vaso-
active intestinal peptide, acetylcholine), all involved in
the regulation of intestinal motility, have been docu-
mented in the 6-OHDA model, thus suggesting that cen-
tral dopaminergic neurodegeneration is associated with
remodeling of enteric neurotransmission [9–12]. In this
context, very scarce attention has been paid to the
possible involvement of enteric tachykininergic pathway
in the pathophysiology of gut motor dysfunctions
associated with PD. This is quite surprising, in view of
the evidence that intrinsic enteric tachykininergic nerves
play a pivotal role in the physiological regulation of GI
motility and that such system undergoes significant rear-
rangements under pathological conditions, including
bowel motor dysfunctions associated with inflammatory
disorders [13, 14].
Enteric neuronal rearrangement represents a common
feature of several bowel disorders sharing the presence
of an inflammatory enteric condition (e.g., inflammatory
bowel diseases, diverticulitis, and irritable bowel syn-
drome) [15]. In this regard, it is noteworthy that pro-
cesses of enteric neuroplastic remodeling [16], as well as
signs of colonic tissue inflammation [17], have been
observed also in PD patients, supporting the hypothesis
that bowel inflammation and the related remodeling of
enteric neurotransmission could contribute to the
pathophysiology of intestinal motor abnormalities
associated with PD. However, whether, and to what
extent, inflammatory bowel alterations can occur also
in experimental models of PD, and above all, whether
such putative changes can stem from dopaminergic
nigrostriatal degeneration, a pathological hallmark of
PD, remain presently unclear.
Based on the above background, the present study was
specifically designed to address two relevant, though yet
unresolved, issues related to the GI pathophysiology in
PD: (1) the impact of nigrostriatal dopaminergic neuro-
degeneration on colonic tachykininergic excitatory mo-
tility and (2) the occurrence of inflammatory responses
in the large bowel and abdominal cavity following the in-
duction of nigrostriatal dopaminergic degeneration.
Methods
Animals
Male Sprague-Dawley rats, 200–250 g body weight, were
used throughout the study. The animals were fed stand-
ard laboratory chow and tap water ad libitum and were
not employed for at least 1 week after their delivery to
the laboratory. They were housed, three in a cage, in
temperature-controlled rooms on a 12-h light cycle at
22–24 °C and 50–60 % humidity. Their care and handling
were in accordance with the provisions of the European
Community Council Directive 86-609 and recognized and
adopted by the Italian Government.
Induction of nigrostriatal neurodegeneration
Animals were anesthetized with 50 mg/kg of sodium
thiopental (i.p.) and placed into a stereotaxic frame
(Stoelting, Wood Dale, IL, USA). Rats received 6-OHDA
(dissolved in saline solution containing 0.02 % of ascor-
bic acid) or saline (controls) unilaterally into two sites of
the right MFB, at the following coordinates (mm) rela-
tive to bregma and dural surface: (i) antero-posterior
(AP) = −4.0, medio-lateral (ML) = −0.8, dorso-ventral
(DV) = −8.0 tooth bar at +3.4 (9 μg/3 μL) and (ii) AP = −
4.4, ML = −1.2, DV = −7.8 tooth bar at −2.4 (7.5 μg/
3 μL)[10]. The injection rate was 1 μL/min using a
Hamilton 10 μL syringe mounting a 26-gauge needle. After
injection, the needle was left in place for 5 min to avoid
leaks. At the end of process, wounds were clipped and ani-
mals allowed to wake up and recover. Animals were eutha-
nized by cervical dislocation 4 and 8 weeks following 6-
OHDA injection. Brains were immediately removed, frozen
on dry ice, and stored at −80 °C, while colonic specimens
were dissected and processed for functional experiments
and other assays as described below. Animals injected with
6-OHDA vehicle and sacrificed after 8 weeks were selected
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as controls, since preliminary experiments, performed with
the specific aim of comparing animals injected with 6-
OHDA vehicle and sacrificed at 4 and 8 weeks, did not
show any significant difference in electrically evoked co-
lonic tachykininergic contractions (data not shown).
The 4- and 8-week time points for the evaluation of
colonic motility and inflammatory response were se-
lected on the basis of previous experiences with the ex-
perimental model of central dopaminergic degeneration
induced by 6-OHDA. In particular, Blandini et al. [10]
observed that rats with central dopaminergic neurode-
generation developed significant colonic functional
and neurochemical changes after 4 weeks from toxin
injection. In addition, in an attempt of documenting
further putative colonic changes occurring in the late
phases of the disease, we decided to include the 8-
week group, as representative of an advanced stage of
intestinal motor dysfunction associated with central
dopaminergic degeneration.
Immunohistochemistry of tyrosine hydroxylase in brain
sections
Serial coronal sections (40 μm), including striatum and
substantia nigra pars compacta (SNc) from both sham-
operated and 6-OHDA animals, were cut on a freezing
sliding microtome and mounted on polylysine-coated
slides. Immunohistochemical staining for tyrosine hy-
droxylase (TH) was carried out to evaluate dopaminergic
terminal damage in the striatum and loss of cell bodies
in the SNc, as previously described [10]. Briefly, sections
containing the striatum and SNc were post fixed in cold,
4 % neutral-buffered formaldehyde (NBF; Carlo Erba,
Milan, Italy), rinsed in Tris-buffered saline (TBS), treated
with 3 % H2O2, and incubated in TBS containing 10 %
normal goat serum together with 0.6 % Triton X-100 for
30 min at room temperature. Sections were incubated
overnight at 4 °C with a mouse anti-TH antibody
(1:2000; Chemicon International, Temecula, CA, USA),
then rinsed in TBS and incubated for 60 min at room
temperature, with a goat biotinylated anti-mouse IgG
antibody (1:1000; Vector Laboratories, Burlingame, CA,
USA). Finally, sections were processed with the avidin-
biotin technique using a commercial kit (Vectastain
ABC Elite kit, Vector laboratories), and reaction prod-
ucts were developed using nickel-intensified 3,3′-diami-
nobenzidine tetrahydrochloride (DAB Substrate Kit for
Peroxidase, Vector Laboratories). After rinsing with TBS,
sections were dehydrated in ascending alcohol concen-
trations, cleared in xylene (Carlo Erba, Milan, Italy), and
coverslipped.
Evaluation of nigrostriatal neurodegeneration
The striatal dopaminergic terminal damage resulting
from 6-OHDA infusion into the MFB was detected by
the absence of TH staining within the striatum and
expressed as the percentage of striatal volume deprived
of TH immunoreactivity, as compared with the overall
striatal volume. The striatal expression of TH was also
evaluated in the brain of sham-operated animals. The
total number of dopaminergic cells in SNc of both
hemispheres was counted using stereological analysis.
Unbiased stereological estimation was made using the
optical fractionator method [18] by the STEREO
INVESTIGATOR software on a Neurolucida computer-
controlled microscopy system (Microbrightfield Inc., VT,
USA). The boundaries of SNc at all levels in the rostro-
caudal axis were defined, with reference to a coronal
atlas of the rat brain [19]. TH-positive cells in the SNc
were counted in every fourth section, on comparable
sections for all experimental groups throughout the
whole nucleus. Counting frames (75 × 75 μm) were
placed at the intersections of a grid (frame size 208.65 ×
161.6 μm) that had been randomly placed over the sec-
tion. Cells were marked if they were TH-positive and
were in focus within the counting area. Results represent
the percentage of the number of TH-positive neurons in
the injected SNc with respect to the intact side (neuron
survival). We set 98 % as cut-off level for the striatal le-
sion and 95 % for the lesion in the SNc.
Recording of contractile activity
The contractile activity of colonic muscle preparations
was recorded as previously described by Fornai et al. [9].
Following sacrifice, the abdomen was immediately
opened and the colon was removed by an incision im-
mediately above the anal end and placed into Krebs so-
lution. The distal colon was anatomically distinguished
from proximal colon by the absence of oblique striae on
the mucosal surface [20]. Longitudinal muscle strips ob-
tained from distal colon, approximately 3-mm wide and
20-mm long, were set up in organ baths containing
Krebs solution, at 37 °C, bubbled with 95 % O2 + 5 %
CO2. The strips were oriented along the longitudinal
axis and were connected to isometric force transducers
(2Biological Instruments, Besozzo, VA, Italy); a tension
of 1.0 g was then slowly applied to the preparations. The
mechanical activity was recorded by BIOPAC MP150
(2Biological Instruments, Besozzo, VA, Italy). The Krebs
solution had the following composition (mM): NaCl 113,
KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2, NaHCO3
25, glucose 11.5 (pH 7.4 ± 0.1). Each preparation was
allowed to equilibrate for at least 30 min, with interven-
ing washings at 10-min intervals. A pair of coaxial plat-
inum electrodes was positioned at a distance of 10 mm
from the longitudinal axis of each preparation to deliver
transmural electrical stimulation by a BM-ST6 stimula-
tor (Biomedica Mangoni, Pisa, Italy). Electrical stimuli
were applied as follows: 10-s single trains (ES),
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consisting of square wave pulses (0.5 ms, 30 mA). At
end of the equilibration period, each preparation was re-
peatedly challenged with electrical stimuli (10 Hz), and
experiments started when reproducible responses were
obtained (usually after two or three stimulations).
Frequency-response curves, at frequencies ranging from
1 to 20 Hz, were constructed under the different in vitro
experimental conditions reported below.
In the first series of experiments, contractions were
assessed in colonic preparations maintained in Krebs
solution containing Nω-nitro-L-arginine methylester (L-
NAME) (100 μM), guanethidine (10 μM), atropine
(1 μM), GR159897 (NK2 receptor antagonists, 1 μM),
and SB218795 (NK3 receptor antagonists, 1 μM), in
order to examine the patterns of colonic excitatory
motor responses mediated by tachykininergic NK1 re-
ceptor pathways.
In the second series, the contractile responses were
induced by direct pharmacological activation of NK1
tachykininergic receptors located on smooth muscle
cells. For this purpose, colonic preparations were main-
tained in Krebs solution containing tetrodotoxin (TTX,
1 μM) and stimulated with exogenous substance P (SP,
0.001–10 μM).
Immunohistochemistry of GFAP, SP, and NK1
Sections from formalin-fixed full-thickness colonic sam-
ples were processed for immunoperoxidase staining, as
previously described [21]. Briefly, sections were incu-
bated overnight at 4 °C with primary antibodies against
glial fibrillary acidic protein (GFAP; code n. Z0334,
DakoCytomation, Glostrup, Denmark), SP (code n. Sc-
21715, Santa Cruz Biotech, California, USA), or NK1
(code n. orb 11133 Biorbyt Limited, Cambridge, UK)
and then exposed to appropriate biotinylated immuno-
globulins, peroxidase-labeled streptavidin complex, and
3,3′-diaminobenzidine tetrahydrochloride (DakoCytoma-
tion, Glostrup, Denmark). For quantitative evaluation,
the immune stained sections were examined by a Leica
DMRB light microscope, and representative photomicro-
graphs were taken by a DFC480 digital camera (Leica
Microsystems, Cambridge, UK). Antigen expression was
evaluated as percentage of positive pixels (PPP) calcu-
lated on the total area examined of myenteric ganglia for
GFAP and SP and longitudinal muscle for NK1 recep-
tors. These values were used to calculate mean values
for each experimental groups.
Histological evaluation of eosinophils and mast cells
Sections from formalin-fixed full-thickness colonic sam-
ples were processed for routine (hematoxylin and eosin)
and histochemical staining (0.1 % toluidine blue in 30 %
ethanol for 15 min) in order to detect mast cells and
eosinophils, which appeared as deep violet cells. The
density of eosinophils and mast cells was evaluated in
the tunica mucosa/submucosa. Cells were counted in
three different sections from each rat, and at least 20
randomly selected microscopic fields were examined in
each section (objective, ×40). Values obtained from all
the examined fields for each rat were averaged and
expressed as cell number per square millimeter of tunica
mucosa/submucosa areas, which were estimated by the
Image Analysis System “L.A.S. software v.4.” These
values were then used to calculate mean values for each
experimental group.
Evaluation of tissue MDA levels
Malondialdehyde (MDA) concentration in specimens of
colonic neuromuscular tissues was evaluated to obtain a
quantitative estimation of membrane lipid peroxidation,
and the assay was performed as previously described
[22]. Colonic tissues were weighed, minced by forceps,
homogenized in 2 ml of cold buffer (20 mMRipa buffer,
pH 7.4) by a polytron homogenizer (QIAGEN), and
spun by centrifugation at 1600g for 10 min at 4 °C. Co-
lonic MDA concentrations were determined with a kit
for colorimetric assay (Calbiochem, San Diego, CA), and
the results were expressed as nmol of MDA per milli-
gram of colonic tissue.
Evaluation of tissue TNF and IL-1β levels
TNF and IL-1β levels in colonic neuromuscular tissues
were measured by enzyme-linked immunosorbent assay
kits (Abcam), as previously described [22]. For this pur-
pose, colonic tissue samples, stored previously at −80 °C,
were weighed, thawed, and homogenized in 0.4 ml of
PBS, pH 7.2/20 mg of tissue at 4 °C and centrifuged at
10,000g for 5 min. Aliquots (100 μL) of supernatants
were then used for assay. Tissue TNF and IL-1β levels
were expressed as picograms per gram of tissue and pi-
cograms per milligram of proteins, respectively.
Isolation of peritoneal macrophages
Rat peritoneal macrophages were harvested as previously
described [23]. Macrophages were collected from 6-
OHDA and control rats, following sacrifice, 4 and
8 weeks after 6-OHDA or saline injection. Cells were
cultured as a monolayer in RPMI 1640 medium (Cellgro,
Mediatech Inc., Herndon, VA), supplemented with 10 %
fetal bovine serum (Gemini Bio-Products, Calabasas,
CA), 2 mM L-glutamine, 100 IU/ml penicillin, and
100 μg/ml streptomycin (Irvine Scientific, Santa Ana,
CA). Monolayers were washed 4 h after plating to remove
non-adherent cells. Cultures were shown to be >98 %
pure macrophages, as assessed by staining of non-
specific esterase and macrophage-specific F4/80 mAb
(data not shown).
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RNA extraction and RT-qPCR
Total RNA was isolated by means of TRIzol reagent
(Invitrogen, Life Technologies, Thermo Fisher Scientific
Inc., CA, USA). The concentration of isolated RNA was
determined with a spectrophotometer, and 2 μg of RNA
were used for the reverse transcription (RT) procedure
(High Capacity cDNA Reverse Transcription Kit, Ap-
plied Biosystems, Thermo Fisher Scientific Inc., CA,
USA). RT was performed in a mixture of 2 μL RT buffer,
0.8 μL dNTP, 2 μL random primer, 1 μL reverse
transcriptase, and nuclease-free water (Amresco LLC,
Solon, USA) up to 10 μL. PCR cycles (Veriti 96-Well
Thermal Cycler, Applied Biosystems, Thermo Fisher Sci-
entific Inc., CA, USA) were set as follows: 25 °C for
10 min, 37 °C for 120 min, and 85 °C for 5 min. Tenfold
dilutions of complementary DNA (cDNA) specimens
were used for the real-time quantitative PCR analysis
(RT-qPCR) procedure. qPCR reactions were performed
with the following primers: inducible nitric oxide syn-
thase (iNOS) 5′-CCTTGTTCAGCTACGCCTTC-3′
(sense) and 5′-CCAGGCCAAATACCGCATAC-3′ (anti-
sense); arginase-1 5′-GGACATCGTGTACATCGGCT-3′
(sense) and 5′-GGGCCTTTTCTTCCTTCCCA-3′ (anti-
sense); 18S 5′-GGGAGCCTGAGAAACGGC-3′ (sense)
and 5′-GGGTCGGGAGTGGGTAATTTT-3′ (anti-sense).
SYBR Green (Applied Biosystems, Thermo Fisher Scientific
Inc., CA, USA) qPCR reactions were run in Light Cy-
cler 480 II Real-Time PCR Instrument (Roche, Basel,
Switzerland). Expression values were normalized to
the housekeeping gene 18S expression.
Drugs and reagents
Atropine sulfate, guanethidine monosulphate, Nω-nitro-
L-argininemethylester, 6-hydroxy dopamine, and ascor-
bic acid were purchased from Sigma Chemicals Co. (St.
Louis, MO, USA). Tetrodotoxin, Substance P, N-acetyl-
L-tryptophan 3,5-bis (trifluoromethyl) benzyl ester,
GR159897, and SB218795 were purchased from Tocris
(Bristol, UK). Mouse anti-TH antibody (1:2000) was pur-
chased from Chemicon International (Temecula, CA,
USA). Biotinylated anti-mouse IgG antibody (1:1000)
and nickel-intensified 3,3′-diaminobenzidine tetrahydro-
chloride (DAB Substrate Kit for peroxidase) were pur-
chased from Vector Laboratories (Burlingame, CA,
USA). Neutral-buffered formaldehyde (NBF) and xylene
were purchased from Carlo Erba (Milan, Italy).
Statistical analysis
The results are presented as mean ± S.E.M. unless other-
wise stated. The significance of differences was evaluated
by Student t test for unpaired data or one-way analysis
of variance (ANOVA) followed by post hoc analysis with
Student-Newman-Keuls or Bonferroni tests. P values
<0.05 were considered significantly different. All statistical
procedures were performed by commercial software
(GraphPad Prism, version 3.0 from GraphPad Software
Inc., San Diego, CA, USA).
Results
Immunohistochemical analysis of TH in brain
As previously observed [9], the unilateral injection of 6-
OHDA into the MFB caused a virtually complete loss of
dopaminergic striatal terminals (98 %) and dopaminergic
nigral neurons (95 %) of the right (injected) hemisphere,
both at weeks 4 and 8. Animals bearing lesions of less
than 98 % in the striatum and 95 % in the SNc were ex-
cluded from the study. Sham-operated rats did not dis-
play differences in TH immunoreactivity between
hemispheres, both at weeks 4 and 8 (data not shown).
In vitro colonic contractile activity
During equilibration, most distal colonic preparations
displayed a rapid spontaneous motor activity, which was
low in amplitude and generally stable throughout the ex-
periment (Fig. 1a).
No significant differences in spontaneous motor activ-
ity were observed when comparing controls (mean amp-
litude: 2.3 g/g tissue) to animals injected with 6-OHDA,
ES 10 Hz ES 10 Hz ES 10 Hz
Control 6-OHDA 4 w 6-OHDA 8 w
Control
6-OHDA 4 w
6-OHDA 8 w
Time (min)
A
B
Fig. 1 Longitudinal smooth muscle preparations of distal colon
isolated from control animals or 6-OHDA rats at weeks 4 and 8 and
maintained in standard Krebs solution. a Representative tracings
displaying colonic spontaneous motor activity under resting condi-
tions. b Representative tracings displaying colonic contractile responses
elicited by electrical stimulation (ES: 0.5 ms, 30 mA, 10 s, 10 Hz)
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both at weeks 4 and 8 (mean amplitude 2.7 and 2.5 g/g
tissue, respectively). Electrically evoked responses con-
sisted of phasic contractions followed, in some cases, by
after-contractions of variable amplitude (Fig. 1b). In co-
lonic preparations from control animals and maintained
in standard Krebs solution, the contractions evoked by
electrical stimulation accounted for 45.2 ± 3.5 g/g tissue
(at 10 Hz). In tissues from 6-OHDA-treated rats after
4 weeks, electrically evoked contractions did not differ
significantly (44.2 ± 1.5 g/g tissue, 10Hz), while they were
significantly reduced in animals after 8 weeks from 6-
OHDA injection (32.9 ± 2.2 g/g tissue, 10 Hz, P < 0.05).
In longitudinal muscle preparations from distal
colon, maintained in Krebs solution containing L-
NAME (100 μM), guanethidine (10 μM), atropine
(1 μM), GR159897 (NK2 receptor antagonists, 1 μM),
and SB218795 (NK3 receptor antagonists, 1 μM), the
electrically evoked NK1-mediated tachykininergic con-
tractions were enhanced after 4 weeks (significant dif-
ference at 10 and 20 Hz) and 8 weeks (significant
difference at 5, 10 and 20 Hz), as compared with con-
trols (Fig. 2a). L-732.138 (NK1 receptor antagonist,
10 μM) almost completely abolished these phasic con-
tractions (90 %).
The application of exogenous substance P (SP, 0.001-
10 μM) to longitudinal smooth muscle preparations
from distal colon in the presence of tretrodotoxin
(1 μM) evoked concentration-dependent concentrations,
which were enhanced 4 and 8 weeks after 6-OHDA in-
jection, as compared with controls (Fig. 2b).
Quantitative immunostaining of GFAP, SP, and NK1 in the
colonic neuromuscular layer
Glial cells of colonic myenteric ganglia displayed GFAP
immunopositivity that was significantly increased in rats
with 6-OHDA-induced nigrostriatal denervation at both
weeks 4 (+41 % vs control) and 8 (+28 % vs control).
Likewise, a significant increase in SP immunostaining
was found in myenteric ganglia of 6-OHDA animals
(+209 % vs control after 4 weeks and +247 % vs control
after 8 weeks), along with an enhancement of NK1 re-
ceptor expression in the longitudinal muscle layer,
both at weeks 4 (+201 % vs control) and 8 (+328 %
vs control) (Fig. 3).
Assessment of MDA, TNF, and IL-1β levels in colonic
neuromuscular tissues
MDA levels in colonic specimens from control rats
accounted for 18.8 ± 2.4 nmol/mg tissue (Fig. 4a). 6-
OHDA-induced nigrostriatal degeneration was associ-
ated with a significant increase in the oxidative stress of
colonic tissues at both weeks 4 (57.6 ± 15.8 nmol/mg tis-
sue; +206.3 % vs control) and 8 (61.4 ± 10.7 nmol/mg
tissue; +226.6 % vs control) (Fig. 4a).
TNF levels in colonic tissues from control animals
accounted for 64.7 ± 7.2 pg/g tissue (Fig. 4b). In colonic
tissues from rats with 6-OHDA-induced nigrostriatal
degeneration, TNF levels were increased at both weeks 4
(208.6 ± 23.7 pg/g tissue; +222.4 %) and 8 (267.4 ±
27.5 pg/g tissue; +313.2 %), as compared with controls
(Fig. 4b).
IL-1β levels in colonic tissues from control animals
accounted for 60.02 ± 16.2 pg/mg proteins (Fig. 4c). In
colonic tissues from rats with 6-OHDA-induced nigros-
triatal degeneration, IL-1β levels were increased at both
weeks 4 (224.5 ± 56.2 pg/mg proteins; +274.1 %) and 8
(255.5 ± 28.1 pg/mg proteins; +325.7 %), as compared
with controls (Fig. 4c).
Tissue distribution and density of eosinophils and mast
cells in the colonic wall
Eosinophils, which were frequently found within the tu-
nica mucosa and submucosa of normal colon, were sig-
nificantly increased in 6-OHDA rats, both at weeks 4
(+32 % vs control) and 8 (+66 % vs control, and +25 %
vs 6-OHDA rats at 4 week), which displayed also spor-
adic eosinophils in the tunica muscularis and along the
myenteric ridge (Fig. 5). Mast cells, which were occa-
sionally detected in controls within the perivascular con-
nective tissue of tunica mucosa, submucosa, and serosa,
were significantly increased in density in 6-OHDA-
treated rats at both time points (+111 and +102 % vs
control, respectively) (Fig. 5).
Pro-inflammatory polarization of peritoneal macrophages
Peritoneal macrophages from normal rats have been
previously shown to express higher levels of iNOS
mRNA than arginase-1 mRNA [24]. Accordingly, peri-
toneal macrophages isolated from control rats displayed
aiNOS/arginase-1 expression ratio accounting for 2.7 ±
0.3 (Fig. 6). In peritoneal macrophages obtained from 6-
OHDA rats at weeks 4 and 8, the iNOS/arginase-1 ex-
pression ratio (reminiscent of macrophage M1/M2
polarization) was significantly increased, as compared
control rats (12.2 ± 2.4 and 15.8 ± 3.7, respectively)
(Fig. 6).
Discussion
To extend current knowledge about changes in the en-
teric excitatory pathways regulating colonic motility
under PD, we examined the impact of nigrostriatal dopa-
minergic degeneration on colonic tachykininergic con-
tractile activity. The present findings support the view
that the induction of nigrostriatal neurodegeneration, a
condition which reflects one of the major pathological
hallmarks of PD, is followed by significant alterations of
distal colonic excitatory tachykininergic neuromotility.
In particular, we observed an increase in the electrically
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Fig. 3 Representative pictures of GFAP, SP, and NK1 immunostaining of cross-sections from full-thickness rat colonic specimens from controls
or 6-OHDA animals at weeks 4 and 8. Scale bar = 50 μm. Column graphs display the quantitative assessment of GFAP and SP immunostaining
in myenteric ganglion area and NK1 receptors in longitudinal muscle area. Each column represents the mean value of PPP ± S.E.M. value (n = 8).
*P < 0.05. CM circular muscle, LM longitudinal muscle
(See figure on previous page.)
Fig. 2 Longitudinal smooth muscle preparations of distal colon isolated from control animals or 6-OHDA rats at weeks 4 and 8. a Tissues were
maintained in Krebs solution, containing L-NAME (100 μM), guanethidine (10 μM), atropine (1 μM), GR159897 (NK2 receptor antagonists, 1 μM),
and SB218795 (NK3 receptor antagonists, 1 μM), and contractile responses were elicited by electrical stimulation (ES: 0.5 ms, 30 mA, 10 s, 1–
20 Hz). Each column represents the mean ± S.E.M value obtained from eight experiments. *P < 0.05, significant difference vs control. Tracings in
the inset on the top of each panel display contractile responses to ES recorded at a frequency of 10 Hz. b Tissues were maintained in standard
Krebs solution containing tetrodotoxin (1 μM), and contractions were evoked by increasing concentration of exogenous substance P (SP, 0.001–
10 μM). Tracings in the inset on the top of each panel display contractile responses to exogenous SP at a concentration of 10 μM. Each point
represents the mean ± S.E.M value (n = 8). *P < 0.05, significant difference vs control
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evoked tachykininergic contractions of longitudinal
muscle preparations from 6-OHDA rats, recorded upon
incubation of colonic tissues with atropine, guanethidine,
L-NAME, and neurokinin NK2 and NK3 receptor antag-
onists, as well as an enhancement of myogenic motor re-
sponses evoked by exogenous application of SP in the
presence of tetrodotoxin to abate neurogenic responses.
Of note, electrically evoked contractions, recorded from
preparations maintained in standard Krebs solution,
were reduced in 6-OHDA rats as compared with con-
trols (see Fornai et al. [9]), despite an increase in tachy-
kininergic neuromotility, as observed in the present
experiments. Analogously, our previous in vivo observa-
tion of a reduced colonic transit in 6-OHDA rats is also
apparently at odds with the present in vitro results
showing an enhanced tachykininergic neuromuscular
activity [9]. However, in our previous study we observed
a significant impairment of in vitro cholinergic
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Fig. 4 MDA (a), TNF (b), and IL-1β (c) levels in colonic tissues from control animals and rats after 4 and 8 weeks from nigrostriatal degeneration
with 6-OHDA. Each column represents the mean ± S.E.M value (n = 8). *P < 0.05, significant difference vs control
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neuromotor activity. In addition, the overall colonic pro-
pulsive motility is known to result from an integrated
combination of circular and longitudinal smooth muscle
contractions regulated by both excitatory and inhibitory
neurotransmitter pathways [25]. Therefore, it is conceiv-
able that the overall contractions recorded from colonic
longitudinal muscle preparations maintained in standard
Krebs solution, as well as the patterns of in vivo colonic
transit, do not necessarily reflect the patterns of con-
tractile responses elicited by specific stimulation of the
excitatory tachykininergic pathway.
In the present study, efforts were then dedicated to in-
vestigate the mechanisms underlying the enhancement
of colonic tachykininergic motility in 6-OHDA rats. As a
first step, we examined whether these motor changes
could depend on variations of the density of myenteric
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Fig. 5 Representative pictures of hematoxylin/eosin- and toluidine blue-stained colonic sections obtained from controls or animals treated with
6-OHDA at weeks 4 and 8. The column graphs display mean values of eosinophil or mast cell density per square millimeter of tunica mucosa/sub-
mucosa areas (cells/mm2) ± S.E.M. value (n = 8). *P < 0.05. Scale bars = 50 μm
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tachykininergic neurons. This goal was pursued by im-
munohistochemical assays, where myenteric ganglia
were labeled with an anti-SP antibody. In these experi-
ments, colonic tissues from 6-OHDA rats displayed a
significant increase in immunopositivity for SP in my-
enteric ganglia. Since the overall density of neurons was
previously shown to not vary in 6-OHDA rat model [9],
our findings suggest that nigrostriatal denervation is as-
sociated with an increased SP expression in myenteric
tachykininergic neurons, which could contribute to the
enhancement of colonic tachykininergic contractile re-
sponses, as shown in our functional experiments. Be-
sides the increase in electrically evoked tachykininergic
contractions of distal colon in 6-OHDA rats, we de-
tected also an enhancement of colonic myogenic con-
tractions elicited by a direct activation of tachykininergic
NK1 receptors with exogenous SP. To better interpret
these results, we went on to examine the expression of
NK1 receptors in colonic specimens by immunohisto-
chemistry, observing an up-regulation of this receptor
subtype in the colon of 6-OHDA rats. To the best of our
knowledge, these experiments provide the first demon-
stration of an altered colonic tachykininergic neuromus-
cular pattern in an experimental model of nigrostriatal
dopaminergic neurodegeneration. Interestingly, a similar
picture has been previously observed in brain tissues
from rats with 6-OHDA-induced central dopaminergic
degeneration, where an increased SP expression was
detected [26]. Overall, based on the present findings, it
is conceivable that an enhancement of tachykininergic
enteric neurotransmission, supported by an increased
expression of both SP and NK1 receptors, could contrib-
ute to the colonic motor abnormalities occurring in 6-
OHDA rats.
A number of previous studies have reported that
changes in enteric tachykininergic pathways are involved
in the pathophysiology of motor GI disorders associated
with inflammatory conditions (i.e., inflammatory bowel
diseases, diverticulitis, and irritable bowel syndrome)
[13, 14]. In particular, an increased SP release has been
observed from neurons of myenteric and submucosal
plexuses, as well as from immune cells of the intestinal
lamina propria (such as monocytes, macrophages, eo-
sinophils, and lymphocytes), isolated from patients with
ulcerative colitis or Crohn’s disease, leading to the hy-
pothesis that the enteric tachykininergic system is in-
volved in the pathogenesis of bowel motor dysfunctions
associated with inflammation [27]. For these reasons,
and considering also previous observations made in
bowel tissue specimens from PD patients [17], in the
second part of the present study, we focused our
attention on investigating the presence of inflammatory
processes in rat colonic tissues following central
dopaminergic neurodegeneration. Interestingly, our re-
sults highlighted clear signs of colonic inflammation in
tissues isolated from 6-OHDA rats, characterized by in-
creased levels of MDA, TNF, and IL-1β, thus suggesting
the presence of gut inflammation and oxidative stress in
the colonic wall. Taken together, these findings provide
the first demonstration that after nigrostriatal degener-
ation the distal colon undergoes a condition of inflam-
matory activation. The presence of bowel inflammation
in 6-OHDA rats was further corroborated by an increase
in eosinophil and mast cell density within the colonic tu-
nica mucosa and submucosa, as well as by the evidence
of glia activation in myenteric ganglia. Of interest, our
results are in line with previous clinical findings display-
ing an increase in pro-inflammatory cytokine concentra-
tions, including TNF and IL-1β, and markers of glial cell
activation (i.e., increase in ganglionic GFAP levels) in co-
lonic biopsies from PD patients [17].
Previous studies have shown that the dorsal motor nu-
cleus of the vagus (DMV)-vagus nerve axis, one of the
earliest CNS sites affected by PD pathology, is signifi-
cantly involved in the pathophysiology of visceral inflam-
mation [28, 29]. Vagal anti-inflammatory signaling
within the GI tract is mediated by activation of nicotinic
receptors [30, 31]. A decay of this signaling—as that oc-
curring in PD—might favor conditions of visceral in-
flammation that may play a substantial role in PD-
related GI dysfunctions [32]. Therefore, we hypothesized
that central dopaminergic neurodegeneration triggered
by 6-OHDA might lead to an inflammatory abdominal
condition through an impairment of the DMV-vagus
nerve anti-inflammatory pathway. To substantiate this
hypothesis, we examined also peritoneal macrophages,
which are known to polarize towards the M1 pro-
inflammatory phenotype, characterized by an increased
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Fig. 6 iNOS/arginase-1 expression ratios in peritoneal macrophages
from control rats and 6-OHDA animals at weeks 4 and 8. Each col-
umn represents the mean ± S.E.M. value (n = 8). *P < 0.05, significant
difference vs control
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expression of iNOS (inducible nitric oxide synthase), or
the M2 “wound healing” phenotype, in which cells
express high levels of arginase-1 [24, 33]. This series of
experiments showed that at both 4 and 8 weeks after 6-
OHDA injection, peritoneal macrophages were signifi-
cantly polarized towards the M1 pro-inflammatory
phenotype, characterized by a high iNOS/arginase-1
expression ratio, thus corroborating the concept that 6-
OHDA animals undergo a condition of abdominal vis-
ceral inflammation following dopaminergic intranigral
neurodegeneration.
Based on the present findings, it is conceivable that an
enhancement of tachykininergic enteric neurotransmis-
sion, supported by an increased expression of both SP
and NK1 receptors, as well as the presence of colonic in-
flammation, could contribute to the enteric motor ab-
normalities occurring after nigrostriatal dopaminergic
degeneration. In this respect, increasing evidence sup-
ports the occurrence of a close interplay between the
SP/NK1 pathway and the onset of immune/inflammatory
responses [27, 34]. In particular, studies on human co-
lonic epithelial cell lines as well as on intestinal tissues
from patients with inflammatory bowel diseases revealed
that inflammatory cytokines, such as TNF and IL-1β,
promoted an up-regulation of NK1 receptor expression
and a marked increase in SP release. In turn, such a
massive increment of SP activity, through an induction of
pro-inflammatory signaling in immune cells (i.e., mitogen-
activated protein kinases and nuclear factor-kB), has been
shown to increase the secretion of pro-inflammatory cyto-
kines (i.e., IL-1β, IL-6, and TNF), thus generating a posi-
tive feedback loop that could drive the chronicization of
the ongoing inflammatory process [27, 34].
Conclusions
In conclusion, our findings indicate that central dopa-
minergic nigrostriatal degeneration is associated with
the occurrence of colonic inflammation and an enhance-
ment of excitatory tachykininergic neurotransmission,
which may contribute to bowel motor alterations. These
findings can provide a basis for better understanding the
mechanisms underlying GI motor abnormalities in PD,
thereby paving the way to the development of suitable
pharmacological treatments for the management of GI
functional disorders associated with PD.
Abbreviations
6-OHDA, 6-hydroxydopamine; DMV, dorsal motor nucleus of the vagus;
GFAP, glial fibrillary acidic protein; GI, gastrointestinal; IL-1β, interleukin1-beta;
MDA, malondialdehyde; MFB, medial forebrain bundle; PD, Parkinson’s
disease; SNc, substantia nigra pars compacta; SP, substance P; TH, tyrosine
hydroxylase; TNF, tumor necrosis factor; TTX, tetrodotoxin
Acknowledgements
We are grateful to the “Boehringer IngelheimFonds” Boehringer Ingelheim
Fonds Foundation for Basic Research in Medicine Schusterstr, Mainz
Germany, for supporting the present work.
Funding
This research was supported by a grant from the Italian Ministry of
Education, University and Research (PRIN 2009, project no. 2009MFSXNZ).
Availability of data and materials
The authors declare that they used standard and commercially available
software, databases, and application/tool for the data analysis. In addition,
the authors declare that they have not a link to include data and materials
and that all data and methods of analysis are included in the manuscript.
The authors are available to share the software, databases, and all relevant
raw data described in the manuscript for testing by reviewers.
Author’s contributions
MF, LA, RC, CP, CS, CI, GL, SC, ET, and KC contributed to acquisition, analysis,
and interpretation of the data. MF, RC, CB, NB, CP, and FB contributed to
acquisition, analysis, and interpretation of data, drafting the manuscript, and
revising it critically. MF, CB, NB, CP, LA, GH, and FB contributed to conception
and design, drafting the manuscript, and revising it critically for important
intellectual content. All the authors have read and approved the final version
of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval
The study protocol was approved by the Ethics Committee of the Italian
Ministry of Health (authorization number 748/2015-PR).
Author details
1Department of Clinical and Experimental Medicine, University of Pisa, Via
Roma 55, 56126 Pisa, Italy. 2Department of Pharmaceutical and
Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
3Laboratory of Functional Neurochemistry, Center for Research in
Neurodegenerative Diseases, “C. Mondino” National Neurological Institute,
27100 Pavia, Italy. 4Department of Medical Chemistry, Medical and Health
Science Center, University of Debrecen, Debrecen 4032, Hungary.
5Department of Surgery and Center for Immunity and Inflammation, Rutgers
New Jersey Medical School, Newark 07103, NJ, USA.
Received: 1 March 2016 Accepted: 31 May 2016
References
1. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S,
Neunlist M, Derkinderen P. The second brain and Parkinson’s disease. Eur J
Neurosci. 2009;30:735–41.
2. Pellegrini C, Antonioli L, Colucci R, Ballabeni V, Barocelli E, Bernardini N,
Blandizzi C, Fornai M. Gastric motor dysfunctions in Parkinson’s disease:
current pre-clinical evidence. Parkinsonism Relat Disord. 2015;21:1407–14.
3. Cloud LJ, Greene JG. Gastrointestinal features of Parkinson’s disease. Curr
Neurol Neurosci Rep. 2011;11:379–84.
4. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein
immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in
cases staged for Parkinson’s disease-related brain pathology. Neurosci
Lett. 2006;396:67–72.
5. Banach T, Zurowski D, Kania D, Thor PJ. Myoelectrical activity of small
intestine in rats with experimental Parkinson’s disease. Folia Med Cracov.
2005;46:119–24.
6. Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S,
Greene JG. Loss of enteric dopaminergic neurons and associated changes
in colon motility in an MPTP mouse model of Parkinson’s disease. Exp
Neurol. 2007;207:4–12.
7. Noorian AR, Rha J, Annerino DM, Bernhard D, Taylor GM, Greene JG.
Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal
motility associated with transgene expression in the vagal system. Neurobiol
Dis. 2012;48:9–19.
8. Blandini F, Armentero MT, Martignoni E. The 6-hydroxydopamine model:
news from the past. Parkinsonism Relat Disord. 2008;14 Suppl 2:S124–129.
Pellegrini et al. Journal of Neuroinflammation  (2016) 13:146 Page 12 of 13
9. Fornai M, Pellegrini C, Antonioli L, Segnani C, Ippolito C, Barocelli E,
Ballabeni V, Vegezzi G, Al Harraq Z, Blandini F, et al. Enteric dysfunctions in
experimental Parkinson’s disease: alterations of excitatory cholinergic
neurotransmission regulating colonic motility in rats. J Pharmacol Exp Ther.
2016;356:233–43.
10. Blandini F, Balestra B, Levandis G, Cervio M, Greco R, Tassorelli C, Colucci M,
Faniglione M, Bazzini E, Nappi G, et al. Functional and neurochemical
changes of the gastrointestinal tract in a rodent model of Parkinson’s
disease. Neurosci Lett. 2009;467:203–7.
11. Zhu HC, Zhao J, Luo CY, Li QQ. Gastrointestinal dysfunction in a Parkinson’s
disease rat model and the changes of dopaminergic, nitric oxidergic,
and cholinergic neurotransmitters in myenteric plexus. J Mol Neurosci.
2012;47:15–25.
12. Levandis G, Balestra B, Siani F, Rizzo V, Ghezzi C, Ambrosi G, Cerri S, Bonizzi
A, Vicini R, Vairetti M, et al. Response of colonic motility to dopaminergic
stimulation is subverted in rats with nigrostriatal lesion: relevance to
gastrointestinal dysfunctions in Parkinson’s disease. Neurogastroenterol
Motil. 2015;27:1783–95.
13. Neunlist M, Aubert P, Toquet C, Oreshkova T, Barouk J, Lehur PA, Schemann
M, Galmiche JP. Changes in chemical coding of myenteric neurones in
ulcerative colitis. Gut. 2003;52:84–90.
14. ter Beek WP, Biemond I, Muller ES, van den Berg M, Lamers CB.
Substance P receptor expression in patients with inflammatory bowel
disease. Determination by three different techniques, i.e., storage
phosphor autoradiography, RT-PCR and immunohistochemistry.
Neuropeptides. 2007;41:301–6.
15. Vasina V, Barbara G, Talamonti L, Stanghellini V, Corinaldesi R, Tonini M, De
Ponti F, De Giorgio R. Enteric neuroplasticity evoked by inflammation.
Auton Neurosci. 2006;126–127:264–72.
16. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal
dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46:559–64.
17. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E,
Bruley des Varannes S, Naveilhan P, Nguyen JM, et al. Colonic inflammation
in Parkinson’s disease. Neurobiol Dis. 2013;50:42–8.
18. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G.
Neuroprotective effect of rasagiline in a rodent model of Parkinson’s
disease. Exp Neurol. 2004;187:455–9.
19. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of
the total number of neurons in thesubdivisions of the rat hippocampus
using the optical fractionator. Anat Rec. 1991;231:482–97.
20. Lindstrom CG, Rosengren JE, Fork FT. Colon of the rat. An anatomic,
histologic and radiographic investigation. Acta Radiol Diagn (Stockh).
1979;20:523–36.
21. Ippolito C, Segnani C, Errede M, Virgintino D, Colucci R, Fornai M, Antonioli
L, Blandizzi C, Dolfi A, Bernardini N. An integrated assessment of
histopathological changes of the enteric neuromuscular compartment in
experimental colitis. J Cell Mol Med.
2015;19:485–500.
22. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G,
Kastsiuchenka O, Duranti E, Virdis A, Vassalle C, et al. Inhibition of adenosine
deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp
Ther. 2007;322:435–42.
23. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, Boons GJ,
Leibovich SJ. An angiogenic switch in macrophages involving synergy
between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.
Am J Pathol. 2003;163:711–21.
24. Li Z, Zhao ZJ, Zhu XQ, Ren QS, Nie FF, Gao JM, Gao XJ, Yang TB, Zhou WL,
Shen JL, et al. Differences in iNOS and arginase expression and activity in
the macrophages of rats are responsible for the resistance against T. gondii
infection. PLoS One.
2012;7:e35834.
25. Bornstein JC, Costa M, Grider JR. Enteric motor and interneuronal circuits
controlling motility. Neurogastroenterol Motil. 2004;16 Suppl 1:34–8.
26. Thornton E, Vink R. Treatment with a substance P receptor antagonist is
neuroprotective in the intrastriatal 6-hydroxydopamine model of early
Parkinson’s disease. PLoS One. 2012;7:e34138.
27. Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease.
Curr Opin Gastroenterol. 2009;25:503–11.
28. Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune
homeostasis. Gut. 2013;62:1214–22.
29. Meregnani J, Clarencon D, Vivier M, Peinnequin A, Mouret C, Sinniger V,
Picq C, Job A, Canini F, Jacquier-Sarlin M, Bonaz B. Anti-inflammatory effect
of vagus nerve stimulation in a rat model of inflammatory bowel disease.
Auton Neurosci. 2011;160:82–9.
30. Matteoli G, Gomez-Pinilla PJ, Nemethova A, Di Giovangiulio M, Cailotto C,
van Bree SH, van Bree SH, Michel K, Tracey KJ, Schemann M, Boesmans W,
et al. A distinct vagal anti-inflammatory pathway modulates intestinal
muscularis resident macrophages independent of the spleen. Gut. 2014;63:
938–48.
31. The FO, Boeckxstaens GE, Snoek SA, Cash JL, Bennink R, Larosa GJ, van den
Wijngaard RM, Greaves DR, de Jonge WJ. Activation of the cholinergic
anti-inflammatory pathway ameliorates postoperative ileus in mice.
Gastroenterology. 2007;133:1219–28.
32. Greene JG. Causes and consequences of degeneration of the dorsal motor
nucleus of the vagus nerve in Parkinson’s disease. Antioxid Redox Signal.
2014;21:649–67.
33. Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the
initiation of inflammation in IBD. Inflamm Bowel Dis. 2014;20:166–75.
34. Goode T, O’Connor T, Hopkins A, Moriarty D, O’Sullivan GC, Collins JK,
O’Donoghue D, Baird AW, O’Connell J, Shanahan F. Neurokinin-1 receptor
(NK-1R) expression is induced in human colonic epithelial cells by
proinflammatory cytokines and mediates proliferation in response to
substance P. J Cell Physiol. 2003;197:30–41.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pellegrini et al. Journal of Neuroinflammation  (2016) 13:146 Page 13 of 13
